Novartis is set to launch its one-off gene therapy Zolgensma for the ultra-rare muscle-wasting disease spinal muscular atrophy (SMA) in Germany at the start of July priced at 1,945,000 euros, and says ...

Shares in Scholar Rock have gone into overdrive after the biotech reported positive phase 3 results with apitegromab in patients with spinal muscular atrophy (SMA), setting up regulatory filings in ...

Chart does not reflect overnight price.

The central government announced a complete GST exemption on 36 lifesaving medicines on Monday September 22, covering cancer therapies, treatments for rare genetic disorders, and drugs for chronic ...

SMA-20 Crossed Above SMA-50 Stocks- 20 day moving avergae above 50 day moving average: The primary application of Simple Moving Average is for analyzing stock trends Multiply the power of your ...